Compare Abeona Therapeutics Inc (ABEO) vs Iron Mountain Inc (IRM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Iron Mountain Inc — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Iron Mountain Inc trades at $114.47 (market cap $34.44B). The key difference: Iron Mountain Inc is far larger — about 92.3× Abeona Therapeutics Inc's market cap, and Iron Mountain Inc pays a 2.99% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | IRM | |
|---|---|---|
Market Cap | $373.32M | $34.44B |
Sector | Health | Real Estate |
52-Week High | $7.23 | $133.06 |
52-Week Low | $4.17 | $78.86 |
Enterprise Value | $228.22M | $53.57B |
Dividend Yield | — | 2.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Iron Mountain (IRM) trades at $115.75, down 1.2% on the day, with strong recent earnings beats and a bullish analyst consensus of $138.67 price target. The stock shows technical bearish signals despite positive momentum news, while fundamentals reveal modest revenue growth to $6.90B in 2025 but declining net margins to 3.76%. Recent debt offerings of $1.5B highlight capital strategy moves amid high leverage.
Outlook remains cautiously optimistic given earnings outperformance and industry tailwinds, but risks include elevated debt levels and margin pressure. The stock offers growth potential with a 65% buy rating from analysts, though investors should weigh technical weakness against fundamental resilience in the information services sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
